GlaxoSmithKline plc

*Prices delayed by at least 15 minutes Get price movement alerts
  • 1,642.75p
  • -1.50p (-0.09%)


GSK share price outperforms as ViiV unveils upbeat trial results

GSK shares outperform as ViiV unveils upbeat trial results

Two-drug HIV regimen found to have similar efficiency to three-drug treatment

3 weeks ago


Get Alerts

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) (LON:GSK) is a global healthcare group active in the research, development, manufacture and marketing of a broad range of innovative medicines and brands.

Headquartered in Brentford, United Kingdom, GlaxoSmithKline was formed in 2000 by the merger of Glaxo Wellcome plc (established by the acquisition of Wellcome plc by Glaxo plc) and SmithKline Beecham plc (formed by the merger of Beecham plc and SmithKline Beckman Corporation).
The group has three main areas of business: Pharmaceuticals, Vaccines and Consumer Healthcare. It has major research centres in the UK, USA, Belgium, Spain and China, 87 manufacturing facilities worldwide, and offices in over 115 countries.
The group is one of the few healthcare companies that conduct research for HIV/AIDS, malaria and tuberculosis – the World Health Organisation’s three priority diseases.
GSK’s latest acquisitions include Okairos AG (May 2013) and an additional 29.3% interest in GlaxoSmithKline Consumer Healthcare Ltd (January 2013).
In 2012, GSK pleaded guilty to criminal charges and agreed to a $3 billion settlement of a health-care fraud case in the United States – the biggest payment by a pharma company in that country.
The GSK group is listed on the London Stock Exchange where it is a constituent of the FTSE 100 Index. GSK has a secondary listing on the New York Stock Exchange.
Andrew Philip Witty is Chief Executive Officer of the group.

Send Feedback. Win £20
0 Brokers added for comparison:
Clear all